Allogene Therapeutics ALLO AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's AFS securities?
- Allogene Therapeutics (ALLO) reported AFS securities of $0 in Q1 2026.
- How has Allogene Therapeutics's AFS securities changed year-over-year?
- Allogene Therapeutics's AFS securities decreased by 100.0% year-over-year, from $55.51M to $0.
- What is the long-term trend for Allogene Therapeutics's AFS securities?
- Over 5 years (2020 to 2025), Allogene Therapeutics's AFS securities has grown at a -47.6% compound annual growth rate (CAGR), from $204.21M to $8.04M.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.